KISS1R Agonist Peptide Programme — Generation 1 Computational Pipeline

Kiss1r Agonist Peptide Programme — Generation 1 Computational Pipeline

KISS1R

Peptide therapeutics — Fertility / Hypogonadism / KISS1R–GPR54 agonism

An end-to-end agent-driven campaign designing modified kisspeptin decapeptide agonists of KISS1R (GPR54), the obligate receptor for kisspeptin and the primary molecular driver of the hypothalamic-pituitary-gonadal (HPG) axis. Clinical validation precedents: MVT-602 (Myovant / Sumitovant, Phase I/II in fertility) and TAK-683 (Takeda) confirm KISS1R as a druggable target for idiopathic hypogonadotropic hypogonadism (IHH). Generation 1 explored a 10-candidate library (C1-01…C1-10) across a 9-gate pipeline (G0–G9). Two leads advanced: C1-01 (PRODIGY Kd 0.64 nM) and C1-02 (PRODIGY Kd ~140 pM).

Description

Team

PeptAI

Research Lead

Organisation

BIO Protocol

Experiment Cost

$25,000.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

The project explicitly states 'NO experimental validation yet conducted' and describes itself as 'pre-experimental' at 'Gate 9 staging.' All evidence presented consists entirely of computational predictions (molecular docking, MD simulations, binding energy calculations, solubility/stability predictions) with no wet-lab experiments performed. The systematic decision tree Question 1 asks whether ANY experimental laboratory work has been conducted - the answer is definitively no, placing this project at TRL 1.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score4.45

Overall Assessment

The KISS1R agonist peptide programme demonstrates strong TRL 1 performance with a weighted score of 4.45/5.0. The project excels in therapeutic relevance (5/5) due to validated target biology, clinical precedents, and rigorous computational design. The mechanism directly addresses a monogenic disease with clear causality. Intellectual property position is favorable (4/5) with novel chemical modifications, though prior art from clinical competitors exists. Therapeutic optionality is moderate (3/5), limited primarily to reproductive endocrinology indications. The project is well-positioned at the TRL 1-2 boundary, pending Gate 9 experimental validation to confirm computational predictions.

Weighted Score

Project Progress

All updates

All categories

Timeline

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

Assessment

Low Confidence

RecommendationPROMOTE

Total Score4.45

Overall Assessment

Weighted Score

Therapeutic Relevance

The mechanism is highly scientifically plausible, targeting KISS1R (GPR54), a well-validated GPCR in the hypothalamic-pituitary-gonadal axis. Loss-of-function mutations in KISS1/KISS1R directly cause idiopathic hypogonadotropic hypogonadism, establishing clear disease causality. Clinical precedents MVT-602 (Phase I/II) and TAK-683 validate KISS1R as a druggable target. The computational pipeline demonstrates rigorous structure-based design against high-resolution cryo-EM structure (PDB 8XGO, 2.68 Å), with predicted sub-nanomolar binding affinities for both candidates.

Therapeutic Optionality

The mechanism has moderate therapeutic optionality. While primarily designed for IHH (affecting 1 in 4,000-10,000 individuals), KISS1R signaling is central to reproductive endocrinology broadly, suggesting potential applications in fertility disorders, polycystic ovary syndrome, and possibly oncology (kisspeptin has metastasis suppressor properties). However, the current scaffold is specifically optimized for KISS1R agonism with limited diversification potential beyond HPG axis indications.

Intellectual Property

The novel peptide modifications (D-Tyr1, Arg(Me)9, azaGly7, N-Ac capping in various combinations) represent patentable composition of matter claims distinct from prior art (native KP-10, MVT-602, TAK-683). The specific structural modifications addressing proteolytic stability provide differentiation. However, the shared C-terminal RF-amide pharmacophore and existence of clinical-stage competitors (MVT-602, TAK-683) create some prior art considerations and freedom-to-operate questions that need careful navigation.